Clinicians will recommend a health app alongside a medicine only when it costs the patient nothing: 96.3% would if it is covered, none at $30 a month
In October 2026, 96.3% of US healthcare professionals on the Brox panel (n=81) were likely to recommend an FDA-cleared app alongside a long-term medicine when insurance covered it and the patient paid $0, but none were likely to when the patient paid $30 a month.
- Who was asked
- US clinicians, 81 clones, US
- When
- October 2026 (fielded 11 October 2026)
- How
- Predicted responses from Brox clones, each built from a long-form interview with a real person.
- What changed from the obvious question
- The obvious question lists what clinicians want from an app, which published reviews already answer without numbers. This study asked the access side instead: at what monthly patient cost an FDA-cleared app stops being recommended, and which single lever (coverage, outcomes evidence, record integration or paid review time) ranks first.
Section 01: What the panel said
- #
96.3%
96.3% of US healthcare professionals are likely to recommend an FDA-cleared app alongside a long-term medicine when insurance covers it and the patient pays $0; when it is not covered and the patient pays $30 a month none are likely to, and at $100 all 81 are very unlikely to
base 81
- #
48.1%
Asked for the one change that would most increase their willingness to recommend an app, 48.1% pick published trial evidence of better outcomes, 35.8% insurance coverage so the patient pays nothing, 14.8% data reaching the health record without extra work, and 1 of 81 being paid for time reviewing app data
base 81 · contrast
- #
61.7%
61.7% say they never recommend a health app or digital therapeutic alongside a prescription medicine today, 38.3% do so rarely and none sometimes or often
base 81 · contrast
- #
44%
Among clinicians who never recommend an app today, 44.0% name coverage as the biggest lever, against 22.6% of those who recommend one rarely (n=31)
base 50 · Never recommend a health app today · caveat
96.3% of US healthcare professionals are likely to recommend an FDA-cleared app alongside a long-term medicine when insurance covers it and the patient pays $0; when it is not covered and the patient pays $30 a month none are likely to, and at $100 all 81 are very unlikely to
02At what monthly cost do clinicians stop recommending a health app?
Before the first dollar. We wrote the same case three times: a patient starting a long-term prescription medicine, with an FDA-cleared app that helps them take it and track symptoms. When insurance covered the app in full and the patient paid $0, 96.3% of US healthcare professionals on the Brox panel (n=81) were likely to recommend it, 54.3% very likely. When insurance did not cover it and the patient paid $30 a month, not one of the 81 was likely to, and 96.3% were unlikely. At $100 a month all 81 were very unlikely.
So the ladder found a cliff, and it sits between free and $30. Of the 44 clinicians who were very likely to recommend the covered app, every one moved to the unlikely end or the midpoint once the patient paid $30. Each rung was reasoned on its own figure: the $30 answers talk about $30 a month, not about the free case.
That reading is ours, not the panel's answer, and the study cannot separate the two things that changed between the first two rungs: the app stopped being covered and it started costing $30. The strictest reading is narrower and still sharp: a covered, free app is recommended by almost everyone, an uncovered one at $30 by no one.
03Is coverage or evidence the bigger lever?
Asked for the one change that would most increase their willingness to recommend an app, 48.1% of clinicians (n=81) picked published trial evidence that patients using it have better outcomes, ahead of insurance coverage at 35.8%. Data reaching the electronic health record without extra work came third at 14.8%, and being paid for time spent reviewing app data was picked by 1 of 81.
That looks like a contradiction of the price ladder, which made cost a hard stop. It is not one. Read together, coverage works as a gate and evidence as a reason: coverage removes the no, a trial creates the yes. A company that wins coverage without outcomes data has a free app clinicians still need a reason to mention.
04How many clinicians recommend an app today?
Very few, and none of them often. 61.7% (n=81) say they never recommend a health app or digital therapeutic alongside a prescription medicine, 38.3% do so rarely, and not one says sometimes or often. Set against the 96.3% who would recommend a covered app, the gap between today's habit and a free, cleared app is large, though a hypothetical always reads warmer than practice.
The clinicians who never recommend an app are the ones who most want the cost gone. Among the 50 who never do, 44.0% name coverage as the lever and 46.0% evidence. Among the 31 who do so rarely, coverage falls to 22.6% and evidence rises to 51.6%, with record integration at 22.6%. A low number here is a finding about willingness to start, not a verdict on apps: the non-users are waiting on the bill, the occasional users on the proof and the workflow.
05What would a digital therapeutics or market access team do with this?
- A reading, not the panel's answer: launch an app alongside a medicine with coverage or a zero patient cost in place, because at $30 a month this panel would not recommend it at all.
- Lead clinician materials with outcomes trial results, which 48.1% rank as the biggest single lever, and treat coverage as the condition for the conversation rather than the message.
- Pitch record integration to the clinicians who already recommend apps occasionally, where it is named by 22.6%, not to the non-users, where it is named by 10.0%.
The pattern matches earlier Brox pages on the cost side of a treatment decision: GLP-1 considerers held back by cost until the price nears $49 a month, and dermatologists who let the plan pick the psoriasis biologic.
06What do people also ask about clinicians and health apps?
- What share of clinicians would recommend a health app alongside a medicine? 96.3% of US healthcare professionals (n=81, October 2026) would be likely to recommend an FDA-cleared app alongside a long-term medicine if insurance covered it in full.
- At what price do doctors stop recommending a digital therapeutic? At $30 a month out of pocket, none of 81 US clinicians were likely to recommend an uncovered FDA-cleared app, and at $100 all 81 were very unlikely to.
- How many doctors recommend health apps today? 61.7% of US clinicians (n=81) say they never recommend a health app or digital therapeutic alongside a prescription medicine, and none do so sometimes or often.
Section 07: What they said, and the interview line it rests on
“I would be very unlikely to recommend it, so a 1. When it comes to prescribing or recommending new treatments and tools, I generally wait until insurance actually covers them. My patient population has a wide range of socioeconomic backgrounds, and patients are already constantly stressed and concerned about unpredictable healthcare costs. Asking them to pay $30 a month out of pocket for an app adds an unnecessary financial barrier, so unless insurance is covering it, I am not going to recommend it.”
Predicted from this line in the interview
“patients are always really concerned about cost, because even if you have quote-unquote good health insurance, you could have really unpredictable costs.”
“For me, it really comes down to published trial evidence that patients using the app have better outcomes. When evaluating any new treatment, intervention, or clinical tool, efficacy and safety are always the top priorities. I consider myself moderately conservative when it comes to adopting new clinical options; I want to see actual clinical trial results and peer-reviewed data showing that it truly moves the needle before recommending it. Seamless EHR integration and cost considerations are certainly helpful from an administrative and workflow standpoint, but proving that it actually improves patient health and adds measurable clinical value is the gold standard.”
Predicted from this line in the interview
“clinical trials and head-to-head type of comparison studies. Those are really the gold standard for us really looking at something critically, before we can say, hey, this is something that really adds value or is really an improvement on our existing regimen.”
“For me, it has to be insurance coverage so the patient pays nothing for the app. In primary care, I deal with the reality of coverage and cost every single day. I can think a tool or medication is clinically fantastic, but if a patient can't access it or it's going to cost them out of pocket, it's a non-starter. My first thought is always what's best for the patient, but the very next question is always, 'Well, what can they actually get?' If insurance covers it completely and there's no financial barrier, I'm infinitely more willing to recommend it because I know they'll actually be able to get it and use it.”
Predicted from this line in the interview
“A lot of times, people are like, well, why'd you choose that medicine? And because that's what your insurance covered, or I know something will be too expensive. It's not because I don't think it's right for you, it's just because you won't have access to it otherwise.”
Section 08: How much should you trust this?
What we would defend
- The cliff between a covered, free app and an uncovered one at $30 a month: 78 of 81 likely at $0, 0 of 81 likely at $30, and each rung reasoned on its own figure.
- That outcomes evidence ranks above coverage as the single lever (39 against 29 of 81), with paid review time almost never chosen (1 of 81).
- That recommending an app is not routine today: 50 of 81 never do and none do so sometimes or often.
What we would not
- Separating coverage from price: the first two rungs changed both at once (covered and free, then uncovered at $30), so whether a covered app with a $30 copay would be recommended is not measured.
- Any threshold between $0 and $30: no rung was tested inside that range.
- The 96.3% as a forecast of real recommendations: it is a stated response to a hypothetical, and 61.7% never recommend an app today.
- Any split by specialty: the panel is weighted towards dermatologists and specialty was not asked, so no specialty figure is claimed.
- The never against rarely contrast as more than direction: the rarely group is 31 clones.
The main limitation
These are 81 clones of US healthcare professionals, weighted towards dermatologists, answering about a generic FDA-cleared app with no product named; the price ladder changed coverage and cost together, so it shows a cliff, not a measured price threshold.
Section 09: How was this run?
| Segment | Clones |
|---|---|
| Never recommend a health app alongside a medicine today | 50 |
| Recommend one rarely | 31 |
Question wording as fielded
- Do you currently prescribe long-term prescription medicines to patients as part of your clinical practice?
- How often do you currently recommend a health app or digital therapeutic to a patient alongside a prescription medicine?
- A patient is starting a long-term prescription medicine you prescribe. An FDA-cleared app that supports taking the medicine and tracking symptoms is available, and the patient's insurance covers it in full, so the patient pays $0. How likely are you to recommend the app alongside the medicine?
- A patient is starting a long-term prescription medicine you prescribe. An FDA-cleared app that supports taking the medicine and tracking symptoms is available, but insurance does not cover it, so the patient pays $30 a month out of pocket. How likely are you to recommend the app alongside the medicine?
- A patient is starting a long-term prescription medicine you prescribe. An FDA-cleared app that supports taking the medicine and tracking symptoms is available, but insurance does not cover it, so the patient pays $100 a month out of pocket. How likely are you to recommend the app alongside the medicine?
- Which ONE of these would most increase your willingness to recommend a health app or digital therapeutic alongside a prescription medicine?
What was not asked, and why
No question named an app, a company, a medicine or a condition, and none asked about prescription digital therapeutics that need a prescription to unlock, about copays on a covered app, or about prices between $0 and $30.
What changed from the obvious question
The obvious question lists what clinicians want from an app, which published reviews already answer without numbers. This study asked the access side instead: at what monthly patient cost an FDA-cleared app stops being recommended, and which single lever (coverage, outcomes evidence, record integration or paid review time) ranks first.
Fielded through Ask Brox on 11 October 2026.
More on How clinicians use AI in practice · Pricing and price sensitivity · Pharma & HCP · Healthcare Professionals (US) panel
Ask this of your own customers: humans@brox.ai
Related insights
All in this topic-
AI summaries of a new drug's trial: 0 of 198 US physicians and other prescribers would rely on one with no sources, 55.1% when every number links to the paper and 72.7% once a named physician has checked it
55.1% 55.1% (109 of 198) would rely on an AI-generated one-page summary of a newly approved medicine's pivotal trial, a 5 or more of 7, when every number links to the exact line of the published paper it comes from, against 0 of 198 when it shows no sources and 72.7% (144 of 198) when a named independent physician has also checked it against the paper. (base 198)
Read -
Only 2 of 173 US physicians discount pharmaceutical promotion because AI wrote it, while 63% discount content no expert has reviewed
2 Almost nobody objects to AI writing the content. They object to nobody checking it. (base 173)
Read -
Health plan pharmacy benefits: 56.5% of members judge them on the price per prescription, and 73.5% would give up their local pharmacy for mail delivery to save $5 a month
56.5% 56.5% of health plan members (113 of 200) say what they pay at the pharmacy for each prescription is the part of their drug coverage that matters most, 41.0% (82) say whether their medicines are covered at all, and 1.5% (3) say using the pharmacy they want near home. (base 200)
Read -
Paying to keep photos and messages out of AI training: 37% would pay $1 a month, 2% would pay $10
37% 37% of US tech users would pay $1 a month to keep their photos and messages out of a free app's AI training (74 of 200), falling to 13.5% at $5 (27) and 2% at $10 (4). (base 200)
Read